These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32125178)

  • 1.
    Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
    Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
    [No Abstract]   [Full Text] [Related]  

  • 2. Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies.
    Visentin R; Schiavon M; Giegerich C; Klabunde T; Man CD; Cobelli C
    IEEE Trans Biomed Eng; 2019 Oct; 66(10):2889-2896. PubMed ID: 30735983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
    Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
    Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL
    Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Pascucci C; Gambelunghe A; Bolli GB; Fanelli CG; Porcellati F
    Diabetes Care; 2021 Jan; 44(1):125-132. PubMed ID: 33444161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles.
    Kawaguchi Y; Sawa J; Sakuma N; Kumeda Y
    J Diabetes Investig; 2019 Mar; 10(2):343-351. PubMed ID: 29947060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison.
    Martin ; Zhou Y; Takagi T; Tian YS
    Int J Clin Pharm; 2022 Jun; 44(3):587-598. PubMed ID: 35476308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
    Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
    Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
    Battelino T; Danne T; Edelman SV; Choudhary P; Renard E; Westerbacka J; Mukherjee B; Pilorget V; Coudert M; Bergenstal RM
    Diabetes Obes Metab; 2023 Feb; 25(2):545-555. PubMed ID: 36263928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
    Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
    J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
    Shiramoto M; Eto T; Irie S; Fukuzaki A; Teichert L; Tillner J; Takahashi Y; Koyama M; Dahmen R; Heise T; Becker RH
    Diabetes Obes Metab; 2015 Mar; 17(3):254-60. PubMed ID: 25425297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects.
    Sieber J; Weinheimer M; Kongable G; Riddle S; Chang YY; Flacke F
    J Diabetes Sci Technol; 2020 Sep; 14(5):898-907. PubMed ID: 31288531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study.
    Yamabe M; Kuroda M; Hirosawa Y; Kamino H; Ohno H; Yoneda M
    J Diabetes Investig; 2019 Mar; 10(2):352-357. PubMed ID: 29989335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins.
    Buzzetti R; Fadini GP; Nicolucci A; Larosa M; Rossi MC; Cucinotta D;
    Nutr Metab Cardiovasc Dis; 2022 Sep; 32(9):2255-2263. PubMed ID: 35961826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simulator with realistic and challenging scenarios for virtual T1D patients undergoing CSII and MDI therapy.
    Estremera E; Cabrera A; Beneyto A; Vehi J
    J Biomed Inform; 2022 Aug; 132():104141. PubMed ID: 35835439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator
    Visentin R; Schiavon M; Giegerich C; Klabunde T; Man CD; Cobelli C
    Annu Int Conf IEEE Eng Med Biol Soc; 2018 Jul; 2018():4905-4908. PubMed ID: 30441443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
    Hompesch M; Patel DK; LaSalle JR; Bolli GB
    Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New insulin types in type 1 diabetes mellitus].
    Mesa J
    Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different.
    Cheng AYY; Patel DK; Reid TS; Wyne K
    Adv Ther; 2019 May; 36(5):1018-1030. PubMed ID: 30929185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.